Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: Outcome in hypertension, allodynia and metabolic complications

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-14

  Dias, Jenny Pena ^a   Talbot, Sébastien ^a   Sénécal, Jacques ^a   Carayon, Pierre ^b   Couture, Réjean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; APOCYNIN; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; CATALASE; GLUCOSE; INSULIN; MESSENGER RNA; NITRIC OXIDE SYNTHASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SSR 240612; SUPEROXIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; 2 ((3 (1,3 BENZODIOXOL 5 YL) 3 (((6 METHOXY 2 NAPHTHYL)SULFONYL)AMINO)PROPANOYL)AMINO) 3 (4 ((2,6 DIMETHYLPIPERIDINYL)METHYL)PHENYL) N ISOPROPYL N METHYLPROPANAMIDE; 2-((3-(1,3-BENZODIOXOL-5-YL)-3-(((6-METHOXY-2-NAPHTHYL)SULFONYL)AMINO)PROPANOYL)AMINO)-3-(4-((2,6-DIMETHYLPIPERIDINYL)METHYL)PHENYL)-N-ISOPROPYL-N-METHYLPROPANAMIDE; KININ; SULFONAMIDE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MORNING DOSAGE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RAT; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL; TREATMENT DURATION; ANIMAL; BLOOD PRESSURE; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; HUMAN; HYPERALGESIA; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; BLOOD PRESSURE; DIABETES COMPLICATIONS; DIOXOLES; DISEASE MODELS, ANIMAL; HUMANS; HYPERALGESIA; HYPERTENSION; INSULIN RESISTANCE; KININS; MALE; NADPH OXIDASE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B1; SULFONAMIDES; SUPEROXIDE DISMUTASE;

EID: 77958535818     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012622     Document Type: Article

References (78)

1. Dias JP, Ismael MA, Pilon M, de Champlain J, Ferrari B, et al. (2007) The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol 152: 280-287.
2. Lungu C, Dias JP, Franca CE, Ongali B, Regoli D, et al. (2007) Involvement of kinin B1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance. Neuropeptides 41: 375-387.
3. Ismael MA, Talbot S, Carbonneau CL, Beausejour CM, Couture R (2008) Blockade of sensory abnormalities and kinin B(1) receptor expression by Nacetyl-L-cysteine and ramipril in a rat model of insulin resistance. Eur J Pharmacol 589: 66-72.
4. Marceau F, Sabourin T, Houle S, Fortin JP, Petitclerc E, et al. (2002) Kinin receptors: functional aspects. Int Immunol 2: 1729-1739.
5. Couture R, Girolami JP (2004) Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol 500: 467-485.
6. Regoli D, Nsa AS, Rizzi A, Gobeil FJ (1998) Bradykinin receptors and their antagonists. Eur J Pharmacol 348: 1-10.
7. El Midaoui A, Ongali B, Petcu M, Rodi D, de Champlain J, et al. (2005) Increases of spinal kinin receptor binding sites in two rat models of insulin resistance. Peptides 26: 1323-1330.
8. El Midaoui A, Wu R, de Champlain J (2002) Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. J Hypertens 20: 1407-1412.
9. El Midaoui A, de Champlain J (2005) Effects of glucose and insulin on the development of oxidative stress and hypertension in animal models of type 1 and type 2 diabetes. J Hypertens 23: 581-588.
10. El Midaoui A, de Champlain J (2002) Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension 39: 303-307.
11. Campos MM, Leal PC, Yunes RA, Calixto JB (2006) Non-peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain. Trends Pharmacol Sci 27: 646-651.
12. Gougat J, Ferrari B, Sarran L, Planchenault C, Poncelet M, et al. (2004) SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)-sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]-methyl]pheny l)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 309: 661-669.
13. Mori MA, Araujo RC, Reis FC, Sgai DG, Fonseca RG, et al. (2008) Kinin B1 receptor deficiency leads to leptin hypersensitivity and resistance to obesity. Diabetes 57: 1491-1500.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
15. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG (1995) Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95: 187-194.
16. Heitzer T, Wenzel U, Hink U, Krollner D, Skatchkov M, et al. (1999) Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int 55: 252-260.
17. Loomis ED, Sullivan JC, Osmond DA, Pollock DM, Pollock JS (2005) Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther 315: 1058-1064.
18. Tawfik HE, Cena J, Schulz R, Kaufman S (2008) Role of oxidative stress in multiparity-induced endothelial dysfunction. Am J Physiol Heart Circ Physio 295: H1736-H1742.
19. Drapeau G, Audet R, Levesque L, Godin D, Marceau F (1993) Development and in vivo evaluation of metabolically resistant antagonists of B1 receptors for kinins. J Pharmacol Exp Ther 266: 192-199.
20. Miller FJ, Jr., Gutterman DD, Rios CD, Heistad DD, Davidson BL (1998) Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 82: 1298-1305.
21. Aoki S, Su Q, Li H, Nishikawa K, Ayukawa K, et al. (2002) Identification of an axotomy-induced glycosylated protein, AIGP1, possibly involved in cell death triggered by endoplasmic reticulum-Golgi stress. J Neurosci 22: 10751-10760.
22. Wada R, Tifft CJ, Proia RL (2000) Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci U S A 97: 10954-10959.
23. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
24. Cloutier F, de Sousa BH, Ongali B, Couture R (2002) Pharmacologic and autoradiographic evidence for an up-regulation of kinin B(2) receptors in the spinal cord of spontaneously hypertensive rats. Br J Pharmacol 135: 1641-1654.
25. Nazarali AJ, Gutkind JS, Saavedra JM (1989) Calibration of 125I-polymer standards with 125I-brain paste standards for use in quantitative receptor autoradiography. J Neurosci Methods 30: 247-253.
26. Anand-Srivastava MB, de Champlain J, Thibault C (1993) DOCA-salt hypertensive rat hearts exhibit altered expression of G-proteins. Am J Hypertens 6: 72-75.
27. Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA, Jr., et al. (2000) Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 97: 8140-8145.
28. Calixto JB, Medeiros R, Fernandes ES, Ferreira J, Cabrini DA, et al. (2004) Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 143: 803-818.
29. Gabra BH, Berthiaume N, Sirois P, Nantel F, Battistini B (2006) The kinin system mediates hyperalgesia through the inducible bradykinin B1 receptor subtype: evidence in various experimental animal models of type 1 and type 2 diabetic neuropathy. Biol Chem 387: 127-143.
30. Quintao NL, Passos GF, Medeiros R, Paszcuk AF, Motta FL, et al. (2008) Neuropathic pain-like behavior after brachial plexus avulsion in mice: the relevance of kinin B1 and B2 receptors. J Neurosci 28: 2856-2863.
31. Hall CE, Hall O (1966) Comparative ability of certain sugars and honey to enhance saline polydipsia and salt hypertension. Proc Soc Exp Biol Med 122: 362-365.
32. Hwang IS, Ho H, Hoffman BB, Reaven GM (1987) Fructose-induced insulin resistance and hypertension in rats. Hypertension 10: 512-516.
33. Vasdev S, Longerich L, Gill V (2004) Prevention of fructose-induced hypertension by dietary vitamins. Clin Biochem 37: 1-9.
34. Cavarape A, Feletto F, Mercuri F, Quagliaro L, Daman G, et al. (2001) Highfructose diet decreases catalase mRNA levels in rat tissues. J Endocrinol Invest 24: 838-845.
35. Nyby MD, Abedi K, Smutko V, Eslami P, Tuck ML (2007) Vascular Angiotensin type 1 receptor expression is associated with vascular dysfunction, oxidative stress and inflammation in fructose-fed rats. Hypertens Res 30: 451-457.
36. Thirunavukkarasu V, Nitha Nandhini AT, Anuradha CV (2004) Effect of alphalipoic acid on lipid profile in rats fed a high-fructose diet. Exp Diabesity Res 5: 195-200.
37. Vasdev S, Ford CA, Longerich L, Parai S, Gadag V, et al. (1999) Aldehyde induced hypertension in rats: prevention by N-acetyl cysteine. Artery 23: 10-36.
38. Pop-Busui R, Sima A, Stevens M (2006) Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 22: 257-273.
39. Rodriguez AI, Pereira-Flores K, Hernandez-Salinas R, Boric MP, Velarde V (2006) High glucose increases B1-kinin receptor expression and signaling in endothelial cells. Biochem Biophys Res Commun 345: 652-659.
40. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116: 1793-1801.
41. Csiszar A, Wang M, Lakatta EG, Ungvari Z (2008) Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol 105: 1333-1341.
42. Paravicini TM, Touyz RM (2008) NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care Suppl 2: S170-S180. Review.
43. Tong X, Schroder K (2009) NADPH oxidases are responsible for the failure of nitric oxide to inhibit migration of smooth muscle cells exposed to high glucose. Free Radic Biol Med 47: 1578-1583.
44. Gao L, Mann GE (2009) Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res 82: 9-20.
45. Li Y, Descorbeth M, Anand-Srivastava MB (2008) Role of oxidative stress in high glucose-induced decreased expression of Gialpha proteins and adenylyl cyclase signaling in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 294(6): H2845-54.
46. San Martín A, Du P, Dikalova A, Lassegue B, Aleman M, et al. (2007) Reactive oxygen species-selective regulation of aortic inflammatory gene expression in Type 2 diabetes. Am J Physiol Heart Circ Physiol 5: H2073-H2082.
47. Clerch LB, Massaro D (1993) Tolerance of rats to hyperoxia. Lung antioxidant enzyme gene expression. J Clin Invest 91: 499-508.
48. Ceriello A, Dello RP, Amstad P, Cerutti P (1996) High glucose induces antioxidant enzymes in human endothelial cells in culture. Evidence linking hyperglycemia and oxidative stress. Diabetes 45: 471-477.
49. Sharpe PC, Liu WH, Yue KK, McMaster D, Catherwood MA, et al. (1998) Glucose-induced oxidative stress in vascular contractile cells: comparison of aortic smooth muscle cells and retinal pericytes. Diabetes 47: 801-809.
50. Majithiya JB, Balaraman RJ (2005) Time-dependent changes in antioxidant enzymes and vascular reactivity of aorta in streptozotocin-induced diabetic rats treated with curcumin. J Cardiovasc Pharmacol 46(5): 697-705.
51. Fernandes L, Ceravolo GS, Fortes ZB, Tostes R, Santos RA, et al. (2006) Modulation of kinin B1 receptor expression by endogenous angiotensin II in hypertensive rats. Regul Pept 136: 92-97.
52. Ceravolo GS, Fernandes L, Munhoz CD, Fernandes DC, Tostes RC, et al. (2007) Angiotensin II chronic infusion induces B1 receptor expression in aorta of rats. Hypertension 50: 756-761.
53. Petcu M, Ongali B, El Midaoui A, de Champlain J, Couture R (2005) Effects of alpha-lipoic acid on kinin B1 and B2 receptor binding sites in the spinal cord of chronically angiotensin-treated rats. Peptides 26: 1331-1338.
54. Kintsurashvili E, Duka I, Gavras I, Johns C, Farmakiotis D, et al. (2001) Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 281: H1778-H1783.
55. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, et al. (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923.
56. Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292: C82-C97.
57. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL (2005) International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57: 27-77.
58. De Brito GH, Carayon P, Ferrari B, Couture R (2010) Contribution of the central dopaminergic system in the anti-hypertensive effect of kinin B1 receptor antagonists in two rat models of hypertension. Neuropeptides 44: 191-198.
59. Dias JP, Étude du rôle des kinines dans les neuropathies et l'hypertension arte ́rielle chez le rat diabe ́tique, Thesis-Universite ́ Montreal, cote W4U58 2008 v.020 ex., 2.
60. Buleon M, Allard J, Jaafar A, Praddaude F, Dickson Z, et al. (2008) Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model. Am J Physiol Renal Physiol 294: F1249-F1256.
61. Chao J, Yin H, Gao L, Hagiwara M, Shen B, et al. (2008) Tissue kallikrein elicits cardioprotection by direct kinin B2 receptor activation independent of kinin formation. Hypertension 52: 715-720.
62. Chao J, Shen B, Gao L, Xia CF, Bledsoe G, et al. (2010) Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem 391: 345-355.
63. Methner C, Donat U, Felix SB, Krieg T (2009) Cardioprotection of bradykinin at reperfusion involves transactivation of the epidermal growth factor receptor via matrix metalloproteinase-8. Acta Physiol (Oxf) 197: 265-271.
64. Kakoki M, Sullivan KA, Backus C, Hayes JM, Oh SS, et al. (2010) Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci U S A 107: 10190-10195.
65. Savvatis K, Westermann D, Schultheiss HP, Tschope C (2010) Kinins in cardiac inflammation and regeneration: insights from ischemic and diabetic cardiomyopathy. Neuropeptides 44: 119-125.
66. Messadi-Laribi E, Griol-Charhbili V, Gaies E, Vincent MP, Heudes D, et al. (2008) Cardioprotection and kallikrein-kinin system in acute myocardial ischaemia in mice. Clin Exp Pharmacol Physiol 35: 489-493.
67. Kakoki M, Smithies O (2009) The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int 75: 1019-1030.
68. Xu J, Carretero OA, Sun Y, Shesely EG, Rhaleb NE, et al. (2005) Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 45: 747-753.
69. Lagneux C, Bader M, Pesquero JB, Demenge P, Ribuot C (2002) Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice. Int Immunopharmacol 2: 815-822.
70. Duka A, Kintsurashvili E, Duka I, Ona D, Hopkins TA, et al. (2008) Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension 51: 1352-1357.
71. Wang PH, Cenedeze MA, Campanholle G, Malheiros DM, Torres HA, et al. (2009) Deletion of bradykinin B1 receptor reduces renal fibrosis. Int Immunopharmacol 9: 653-657. S1567-5769.
72. Kakoki M, Takahashi N, Jennette JC, Smithies O (2004) Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci U S A 101: 13302-13305.
73. Kakoki M, Kizer CM, Yi X, Takahashi N, Kim HS, et al. (2006) Senescenceassociated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest 116: 1302-1309.
74. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, et al. (2001) Vasoactive potential of the B(1) bradykinin receptor in normotension and hypertension. Circ Res 88: 275-281.
75. Seguin T, Buleon M, Destrube M, Ranera MT, Couture R, et al. (2008) Hemodynamic and renal involvement of B1 and B2 kinin receptors during the acute phase of endotoxin shock in mice. Int Immunopharmacol 8: 217-221.
76. Rodrigues ES, Martin RP, Felipe SA, Bader M, Oliveira SM, et al. (2009) Cross talk between kinin and angiotensin II receptors in mouse abdominal aorta. Biol Chem 390: 907-913.
77. Rodrigues ES, Martin RP, Pesquero JB, Shimuta SI (2010) Lack of kinin receptors affected ACE expression in mice abdominal aorta. Basic and Clinical Pharmacology and Toxicology 107(suppl.1, paper No: 2813.
78. Shariat-Madar Z, Mahdi F, Warnock M, Homeister JW, Srikanth S, et al. (2006) Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 108: 192-199.